Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma

Date
2021
Author
Di Bartolomeo, M.
Mandala, M.
Muro, K.
Van Cutsem, E.
Kobie, J.
Cristescu, R.
Aurora-Garg, D.
Lu, J.
Shih, C-S
Adelberg, D.
Cao, Z. A.
Fuchs, C. S.
Shitara, K.
ÖZGÜROĞLU, Mustafa
Bang, Y-J
Ryu, M-H
Caglevic, C.
Chung, H. C.
Metadata
Show full item record
Abstract
Background: In the phase III KEYNOTE-061 trial (NCT02370498), pembrolizumab did not significantly improve overall survival versus paclitaxel as second-line therapy for gastric/gastroesophageal junction (GEJ) adenocarcinoma with programmed death-ligand 1 (PD-L1) combined positive score (CPS) >= 1 tumors. The association of tissue tumor mutational burden (tTMB) status and clinical outcomes was determined, including the relationship with CPS and microsatellite instability-high (MSI-H) status.
URI
http://hdl.handle.net/20.500.12627/168922
https://doi.org/10.1016/j.annonc.2021.05.803
Collections